FindTrial
Sign In

Clinical presentations of steroid modified fungal infection and identification of causative fungus using MALDI TOF ( Matrix assisted laser desorption/Ionisation â?? Time of flight ) technology

Clinical spectrum and mycological delineation of Tinea incognito using matrix assisted laser desorption / ionisation - Time of flight (MALDI-TOF)Technology

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/06/053876
Enrollment
71
Registered
2023-06-14
Start date
Unknown
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue

Interventions

None listed

Sponsors

GAYATHRI SANTHOSH
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of all age and sex. 2. All the patients with clinical diagnosis of tinea incognito involving the glabrous skin.

Exclusion criteria

Exclusion criteria: 1. Patients with other pre-existing skin disorders. 2. Patients with exclusive Tinea Capitis

Design outcomes

Primary

MeasureTime frame
The study will help us analyse the various clinical presentations & identify the fungal species associated with it. It also shines light on the unregulated sale and unsupervised use of topical steroids and fixed dose combination creams (FDC) containing steroids resulting in a difficult to manage and resistent form of dermatophytosis. Timepoint: 18 months—

Secondary

MeasureTime frame
The results will help us find out the treatment resistent fungal species caused by the unregulated use of steroids.Timepoint: 18 months—

Countries

India

Contacts

Public ContactDR RAMESHA BHAT M

FATHER MULLER MEDICAL COLLEGE

rameshderma@gmail.com9845084224

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026